High performance, diagnostic rapid point-of-care (POC) flow-based tests can quickly deliver reliable results in challenging settings. When designing a new test and designing out a component in an existing test-what are the key considerations and what will be needed in the future?
Commercializing a test or assay as quickly as possible is critical to success. Find out how diagnostic design services, lyophilization and custom capabilities can provide capacity, resources and expertise to improve speed to market now and in the future.
Strategic collaboration enables the development of diagnostic tests, assays and services for a wide range of applications. Hear about recent collaborations that have resulted in successful test development and set a path for future development.
High throughput NGS techniques are revolutionizing genomics from massively parallel whole genome sequencing to targeted sequencing approaches. Find out how to simplify your sequencing approaches for more detailed data, better diagnosis, and more targeted treatments to address current and future demands.
Recent technological advancements have made single-cell omics an increasingly powerful tool for diagnosis, treatment response prediction, and treatment selection, particularly for cancer. Learn about the opportunities for improving results in this growing field.
Recent years have seen the development and adaptation of several approaches for nucleic acid isolation, aiming to improve speed, throughput, and reproducibility. Find out how to optimize results, particularly for liquid biopsy and viral samples now and in the future.
All sessions will be available for on-demand viewing following the broadcast.
Once the event opens, please click on the 'Go To Event' button and navigate to Webinars & Resources to view the webinars within the summit.
Advancing the development and manufacture of therapeutics
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.
Improving access to life-changing therapies that transform human health
Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.
Cytiva is a global life sciences leader with over 7000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients.
Find out more at Cytiva.com
Abingdon Health is a technology-enabled lateral flow diagnostics company providing leading-edge rapid testing solutions to a multi-industry, global client base. Abingdon Health provides lateral flow assay development and smartphone reader solutions alongside Europe’s largest rapid test manufacturing capacity. A multi-disciplinary team forms the foundations of our services and a partnership-led approach alongside a focus on operational excellence produces reliable products irrespective of their complexity. Established supply chain and manufacturing processes are tailored to assay specifications and market demand for continuity of supply.
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost. Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONTM drug candidate, a targeted form of the standard-of-care Doxorubicin, into the clinic by the first half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics business unit works with partners world-wide to develop Affimer proteins for evaluation by those third parties with the objective of establishing royalty bearing license deals with a particular focus on the diagnostics sector. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.
BioDot is the leading provider of automated, ultralow-volume, non-contact fluid dispensing platforms for R&D applications and commercial-scale manufacturing across diagnostics and life sciences, medical products and applied industrial markets. Its technologies are integral to production of point-of-care diagnostics for infectious diseases, allergy tests and diabetes maintenance as well as veterinary medicine and environmental applications. BioDot, founded in 1994, is based in Irvine, California and has international offices in Europe and Asia.
Biogazelle is a Contract Research Organization (CRO) specializing in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. We hold a unique forefront position in the application of quantitative PCR, digital PCR and dedicated RNA sequencing workflows, optimized for quantification of coding and non-coding genes, on precious clinical samples such as liquid biopsies and formalin-fixed, paraffin-embedded (FFPE) tissues. Our aim is to accelerate the development of therapeutics, including small molecules, RNA targeted drugs, and adoptive cell therapies.
Medidee is a leading contract research organization (CRO) and regulatory affairs (RA) and quality assurance (QA) consulting firm for in-vitro diagnostics (IVD) and medical devices with 12 offices in EU, USA and APAC. We deliver strategic, tactical and implementation services to a wide range of global and start-ups. Medidee is very active on MedTech innovation and supports the full product lifecycle from sciences to market. Medidee is at the forefront of the transformation of the IVD industry, including a steep change of regulatory expectations, the digitalization of products and the shift towards the point-of-care.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events